An open-label, phase III study to evaluate the efficacy, safety and PK [pharmacokinetics] of MRA [tocilizumab] in patients with pJIA [polyarticular juvenile idiopathic arthritis]
Phase of Trial: Phase III
Latest Information Update: 13 Aug 2007
At a glance
- Drugs Tocilizumab (Primary)
- Indications Juvenile rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Chugai Pharmaceutical
- 31 Aug 2018 Biomarkers information updated
- 13 Aug 2007 Status changed from in progress to completed.
- 22 Dec 2005 New trial record.